Safety of mTOR inhibitors in breast cancer

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Metastatic breast cancer treatment faces challenges due to therapy resistance and relapse.
• Understanding dysregulated signaling pathways is crucial for improving patient outcomes.
• There is a significant unmet need for novel therapeutic agents to overcome treatment resistance.

Purpose of the Study:

• To review the mechanism of action of PI3K/AKT/mTOR pathway inhibitors in breast cancer.
• To evaluate the safety and efficacy of mTOR inhibitors in breast cancer treatment.
• To outline strategies for managing adverse events associated with mTOR inhibitors.

Main Methods:

• Review of existing literature on PI3K/AKT/mTOR pathway inhibition.
• Analysis of clinical data on everolimus and other mTOR inhibitors.
• Discussion of adverse event management and prevention strategies.

Main Results:

• PI3K/AKT/mTOR pathway inhibition is a promising strategy for enhancing targeted therapies.
• Everolimus is approved for hormone-receptor-positive advanced breast cancer post-aromatase inhibitor therapy.
• mTOR inhibitors demonstrate an acceptable safety profile in breast cancer patients.

Conclusions:

• Inhibition of the PI3K/AKT/mTOR pathway improves efficacy in estrogen receptor-positive breast cancer.
• mTOR inhibitors offer a manageable safety profile with potential for dose adjustment.
• Targeted therapy combined with mTOR inhibition represents a promising approach for breast cancer treatment.